International Journal of Hematology

, Volume 103, Issue 5, pp 545–553 | Cite as

Expression of activated molecules on CD5+B lymphocytes in autoimmune hemolytic anemia

  • Hongli Zhu
  • Wenyan Xu
  • Hong Liu
  • Huaquan Wang
  • Rong Fu
  • Yuhong Wu
  • Wen Qu
  • Guojin Wang
  • Jing Guan
  • Jia Song
  • Limin XingEmail author
  • Zonghong ShaoEmail author
Original Article


To investigate the expression of activation molecules on CD5+B lymphocytes in peripheral blood of autoimmune hemolytic anemia (AIHA)/Evans patients. The expression of CD80, CD86, and CD69 on CD5+B lymphocytes was detected using flow cytometry in 30 AIHA/Evans patients, 18 normal controls (NC) and nine chronic lymphocytic leukemia (CLL) patients. CD80 on CD5+B lymphocytes in untreated patients was higher than that in remission patients (P < 0.05), NC (P < 0.01) and CLL patients (P < 0.01). CD80 on CD5+B lymphocytes was higher than that on CD5B lymphocytes in untreated patients (P > 0.05), but lower than those of CD5B lymphocytes in remission patients and NC (P < 0.05). CD86 on CD5+B lymphocytes of untreated patients was higher than that of remission patients (P < 0.05), NC (P < 0.01). CD86 on CD5+B lymphocytes of CLL was higher than that of NC, remission (P < 0.05), and untreated patients (P > 0.05). CD80 and CD86 on CD5+B lymphocytes was negatively correlated with hemoglobin (HB), C3, C4 (P < 0.05) and positively correlated with reticulocyte (Ret) (P < 0.05). CD69 on CD5+ and CD5B lymphocytes of CLL was higher than those of AIHA/Evans patients and NC (P < 0.05). The active molecules on CD5+B lymphocytes in peripheral blood of AIHA/Evans patients differ from those on CD5 and clonal CD5+B lymphocytes.


Autoimmune hemolytic anemia CD5+B lymphocytes CD80 CD86 CD69 



This work was supported by grants from application foundation and advanced technology research project of Tianjin (15JCYBJC27300), National Natural Science Foundation of China (81370607), Science and Technology Foundation of Tianjin Health Bureau (09KZ108).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12185_2016_1964_MOESM1_ESM.pdf (1.4 mb)
Supplementary material 1 (PDF 1481 kb)
12185_2016_1964_MOESM2_ESM.pdf (1.5 mb)
Supplementary material 2 (PDF 1506 kb)
12185_2016_1964_MOESM3_ESM.pdf (1.7 mb)
Supplementary material 3 (PDF 1784 kb)
12185_2016_1964_MOESM4_ESM.pdf (5 mb)
Supplementary material 4 (PDF 5111 kb)
12185_2016_1964_MOESM5_ESM.pdf (183 kb)
Supplementary material 5 (PDF 182 kb)


  1. 1.
    Cioca DP, Kitano K. Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia. Leukemia. 2002;16:335–43.CrossRefPubMedGoogle Scholar
  2. 2.
    Tibaldi E, Brunati AM, Zonta F, Frezzato F, Gattazzo C, Zambello R, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2011;25:1768–81.CrossRefPubMedGoogle Scholar
  3. 3.
    Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev. 2006;5:403–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Limin Xing, Shao Zonghong Fu, Rong Liu Hong, Jun Shi, Jie Bai, et al. CD5+ B lymphocytes in the bone morrow of autoimmunic hemocytopenia patients and its clinical significance. Chin J Pract Intern Med. 2005;25:39–41 (in Chinese).Google Scholar
  5. 5.
    Zhang ZN. Standard of diagnosis and curative effect of hematopathy. Beijing: Science Press; 2007. p. 68–71 (in Chinese).Google Scholar
  6. 6.
    Neff AT. Autoimmune hemolytic anemias. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, editors. Wintrobe’s clinical hematology. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1157–82.Google Scholar
  7. 7.
    Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130:325–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Soldevila G, Raman C, Lozano F. The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Curr Opin Immunol. 2011;23:310–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Miyazawa M, Boyse EA, Aoki T, Old LJ. Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci. 1968;170:175–93.CrossRefPubMedGoogle Scholar
  10. 10.
    HayakawaK Hardy RR, Parks DR, Herzenberg LA. The “Ly-1 B” cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med. 1983;157:202–18.CrossRefGoogle Scholar
  11. 11.
    Defrance T, Vanbervliet B, Durand I, Banchereau J. Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells. Eur J Immunol. 1989;19:293–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Freedman AS, Freeman G, Whitman J, Segil J, Daley J, Levine H, et al. Expression and regulation of CD5 on in vitro activated human B cells. Eur J Immunol. 1989;19:849–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Cantaert T, Doorenspleet ME, Francosalinas G, Paramarta JE, Klarenbeek PL, Tiersma Y, et al. Increased numbers of CD5+B lymphocytes with a regulatory phenotype in spondylarthritis. Arthritis Rheum. 2012;64:1859–68.CrossRefPubMedGoogle Scholar
  14. 14.
    Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood. 1996;87:2615–20.PubMedGoogle Scholar
  15. 15.
    Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett. 2006;104:70–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol. 2005;130:809–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Evans DE, Munks MW, Purkerson JM, Parker DC. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J Immunol. 2000;164:688–97.CrossRefPubMedGoogle Scholar
  18. 18.
    Clatza A, Bonifaz LC, Vignali DA, Moreno J. CD40-induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation. J Immunol. 2003;171:6478–87.CrossRefPubMedGoogle Scholar
  19. 19.
    Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem. 2002;277:7766–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Podojil JR, Miller SD. Targeting the B7 family of co-stimulatory molecules: successes and challenges. BioDrugs. 2013;27:1–13.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lim TS, Goh JK, Mortellaro A, Lim CT, Hämmerling GJ, Ricciardi-Castagnoli P. CD80 and CD86 differentially regulate mechanical interactions of T-cells with antigen-presenting dendritic cells and B-cells. PLoS One. 2012;7:e45185.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Vazquez BN, Laguna T, Carabana J, Krangel MS, Lauzurica P. CD69 gene is differentially regulated in T and B cells by evolutionarily conserved promoter-distal elements. J Immunol. 2009;183:6513–21.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Vance BA, Harley PH, Backlund PS, Ward Y, Phelps TL, Gress RE. Human CD69 associates with an N-terminal fragment of calreticulin at the cell surface. Arch Biochem Biophys. 2005;438:11–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Lewkowich IP, Rempel JD, HayGlass KT. Prevention of allergen-specific, Th2-biased immune responses in vivo: role of increased IL-12 and IL-18 responsiveness. J Immunol. 2005;175:4956–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Pajusto M, Ihalainen N, Pelkonen J, Tarkkanen J, Mattila PS. Human in vivo-activated CD45R0(+) CD4(+) T cells are susceptible to spontaneous apoptosis that can be inhibited by the chemokine CXCL12 and IL-2,-6,-7, and-15. Eur J Immunol. 2004;34:2771–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Del PG, Del PM, Zucchetto A, Luciano F, BuccisanoF Rossi FM, et al. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica. 2012;97:279–87.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2016

Authors and Affiliations

  • Hongli Zhu
    • 1
  • Wenyan Xu
    • 1
  • Hong Liu
    • 1
  • Huaquan Wang
    • 1
  • Rong Fu
    • 1
  • Yuhong Wu
    • 1
  • Wen Qu
    • 1
  • Guojin Wang
    • 1
  • Jing Guan
    • 1
  • Jia Song
    • 1
  • Limin Xing
    • 1
    Email author
  • Zonghong Shao
    • 1
    Email author
  1. 1.Department of HematologyGeneral Hospital, Tianjin Medical UniversityTianjinChina

Personalised recommendations